Juvenile hemochromatosis is an iron-overload disorder caused by mutations in the genes encoding the major iron regulatory hormone hepcidin (HAMP) 1 and hemojuvelin (HFE2) 2 . We have previously shown that hemojuvelin is a co-receptor for bone morphogenetic proteins (BMPs) and that BMP signals regulate hepcidin expression and iron metabolism 3, 4 . However, the endogenous BMP regulator(s) of hepcidin in vivo is unknown. Here we show that compared with soluble hemojuvelin (HJV.Fc), the homologous DRAGON.Fc is a more potent inhibitor of BMP2 or BMP4 but a less potent inhibitor of BMP6 in vitro. In vivo, HJV.Fc or a neutralizing antibody to BMP6 inhibits hepcidin expression and increases serum iron, whereas DRAGON.Fc has no effect. Notably, Bmp6-null mice have a phenotype resembling hereditary hemochromatosis, with reduced hepcidin expression and tissue iron overload. Finally, we demonstrate a physical interaction between HJV.Fc and BMP6, and we show that BMP6 increases hepcidin expression and reduces serum iron in mice. These data support a key role for BMP6 as a ligand for hemojuvelin and an endogenous regulator of hepcidin expression and iron metabolism in vivo.
Juvenile hemochromatosis is an iron-overload disorder caused by mutations in the genes encoding the major iron regulatory hormone hepcidin (HAMP) 1 and hemojuvelin (HFE2) 2 . We have previously shown that hemojuvelin is a co-receptor for bone morphogenetic proteins (BMPs) and that BMP signals regulate hepcidin expression and iron metabolism 3, 4 . However, the endogenous BMP regulator(s) of hepcidin in vivo is unknown. Here we show that compared with soluble hemojuvelin (HJV.Fc), the homologous DRAGON.Fc is a more potent inhibitor of BMP2 or BMP4 but a less potent inhibitor of BMP6 in vitro. In vivo, HJV.Fc or a neutralizing antibody to BMP6 inhibits hepcidin expression and increases serum iron, whereas DRAGON.Fc has no effect. Notably, Bmp6-null mice have a phenotype resembling hereditary hemochromatosis, with reduced hepcidin expression and tissue iron overload. Finally, we demonstrate a physical interaction between HJV.Fc and BMP6, and we show that BMP6 increases hepcidin expression and reduces serum iron in mice. These data support a key role for BMP6 as a ligand for hemojuvelin and an endogenous regulator of hepcidin expression and iron metabolism in vivo.
Secreted by the liver 5 , hepcidin inhibits intestinal iron absorption and macrophage iron release by decreasing cell surface expression of the iron exporter ferroportin 6 . Hepcidin is upregulated by iron administration 5, 7, 8 and inhibited by anemia 7 . Hepcidin deficiency and unchecked ferroportin activity are the common pathogenic mechanisms underlying the genetic iron-overload disorder hereditary hemochromatosis 9 . Hepcidin is also upregulated by inflammatory cytokines, and hepcidin excess is implicated in the pathogenesis of anemia of inflammation 5, 7, 8, [10] [11] [12] .
Recently, a role for the BMP signaling pathway in hepcidin regulation was discovered 3, 4, 13 . BMPs are members of the TGF-b superfamily, which comprises over 40 ligands 14 . BMP-TGF-b superfamily ligands initiate an intracellular signaling cascade by binding to a complex of type I and type II serine-threonine kinase receptors. The activated receptor complex phosphorylates intracellular Smad proteins, which translocate to the nucleus to modulate gene expression. Reduction of hepatic BMP signaling by a liverspecific conditional knockout of the common BMP-TGF-b intracellular mediator Smad4 (ref. 13 ), or by mutations in the BMP co-receptor HFE2 (refs. 2, 3, 15, 16) , is associated with inappropriately low hepcidin expression and iron overload. We and others have shown that BMP signals positively increase hepcidin expression at the transcriptional level in vitro 3, 4, 13, 17, 18 . We have also shown that iron administration in vivo increases hepatic BMP signaling 19 and that BMP administration in vivo increases hepcidin expression and reduces serum iron 4 . Conversely, inhibition of endogenous BMP signaling with soluble hemojuvelin (HJV.Fc) or with the small-molecule BMP inhibitor dorsomorphin inhibits hepcidin expression and increases serum iron in vivo 4, 19 . Presumably, the mechanism by which HJV.Fc inhibits hepcidin is by binding to endogenously secreted BMP ligands and preventing their interaction with cell surface signaling receptors 4 .
Hemojuvelin (also known as RGMc) is a member of the repulsive guidance molecules (RGM) family, including RGMa and DRAGON (RGMb). RGM family members share 50-60% amino acid identity 20 . Like hemojuvelin, RGMa 21 and DRAGON 22 also bind BMP ligands and function as co-receptors for the BMP signaling pathway. To explore other BMP inhibitors as potential hepcidin-lowering agents, we tested whether purified soluble DRAGON fused to the Fc portion of human IgG1 (DRAGON.Fc) inhibited BMP induction of hepcidin expression in human hepatoma-derived Hep3B cells in a manner similar to HJV.Fc 4 . DRAGON.Fc significantly inhibited hepcidin promoter induction by BMP2 or BMP4 but was less effective in inhibiting BMP5, BMP6 or BMP7 and did not inhibit BMP9 (Fig. 1a) . In comparison with HJV.Fc, DRAGON.Fc was significantly more potent against BMP2 (Fig. 1b) and BMP4 (Fig. 1c) but less potent against BMP6 (Fig. 1d) . DRAGON.Fc also inhibited endogenous HAMP mRNA expression in hepatoma-derived HepG2 cells, in which basal hepcidin expression is dependent in part on endogenous BMP2, BMP4 and BMP6 ligands 4 ( Supplementary Fig. 1 ).
We then tested whether DRAGON.Fc administration affected hepcidin expression and iron metabolism in vivo. HJV.Fc at a similar dose was used as a positive control. In contrast to HJV.Fc, DRAGON.Fc had no effect on hepatic Hamp mRNA (Fig. 1e) , splenic ferroportin ( Supplementary Fig. 2a,b) , serum iron (Fig. 1f) , serum transferrin saturation, or liver or spleen iron content ( Supplementary  Fig. 2c ,e) compared with those in mock-treated control mice. Anti-BMP2 activity in the serum of DRAGON.Fc-treated mice was confirmed by the ability of this serum to inhibit BMP2 induction of hepcidin promoter activity in vitro compared with serum from mocktreated mice ( Supplementary Fig. 2f ).
Because DRAGON.Fc-despite its higher potency in vitro as an inhibitor of BMP2 and BMP4 compared with HJV.Fc-had no effect in vivo and because DRAGON.Fc was less potent than HJV.Fc at inhibiting BMP6, we hypothesized that the BMP6-inhibiting properties of HJV.Fc are important for its effects as a hepcidin-lowering agent in vivo. We therefore tested whether a neutralizing antibody to BMP6 (anti-BMP6) affected hepcidin expression and serum iron levels in mice. The antibody selectively inhibited BMP6-induced hepcidin promoter activity in vitro but had no significant effect on BMP2, BMP4 or BMP9 (Fig. 2a) . Anti-BMP6 showed some inhibitory activity against BMP7, and to a lesser extent BMP5, at higher concentrations, but significantly less than with BMP6 (Fig. 2a) . This cross-reactivity is not surprising because BMP6, BMP7 and BMP5 have 71-80% amino acid identity and form a subfamily within the BMP ligands 23 . To minimize the effects of this cross-reactivity, we used e f the lowest effective dose of anti-BMP6 for subsequent in vivo experiments. Cross-reactivity with BMP7 was also less of a concern because BMP7 is not a ligand for hemojuvelin, is not expressed in the liver and is not thought to be an important endogenous hepcidin regulator 4, 23 . Treatment with anti-BMP6 at 10 mg per kg body weight for 3 d significantly reduced hepatic Hamp mRNA expression, by B50%, and increased serum iron and transferrin saturation compared with those in mock-treated control mice (Fig. 2b-d) . Anti-BMP6 treatment also caused a trend toward reduced hepatic mRNA expression of Id1-another expected target of BMP6 (ref. 21 ) that we assessed as a control-by B60% (Supplementary Fig. 3 ). Similar results were found with a lower dose of anti-BMP6, although this dose was less effective ( Supplementary Fig. 4 )
To validate the importance of endogenous BMP6 in regulating hepcidin expression and iron metabolism in vivo, we examined 4-and 8-week-old Bmp6-null mice previously generated by other researchers, which had been found to have some mild delays in bone formation during development but no other overt defects 24 . Compared with wild-type mice, 8-week-old Bmp6-null mice showed significantly (tenfold) reduced hepatic Hamp mRNA expression, increased splenic ferroportin expression, and increased serum iron, with serum transferrin saturation approaching 100% (Fig. 3a-e) . Liver iron content was significantly increased in the Bmp6-null mice, by 6-fold at 4 weeks and 20-fold at 8 weeks ( Supplementary Fig. 5a and Fig. 3f,g ). Significant iron accumulation was also evident in the hearts and pancreases of Bmp6-null mice, whereas spleen iron content was reduced ( Fig. 3h and Supplementary Fig. 5b ). The degree of iron overload in the livers of 8-weekold Bmp6-null mice appears comparable to that reported in Hfe2 -/-mice at a similar age 15, 16 . Thus, Bmp6-null mice have a phenotype that resembles mouse models of juvenile hemochromatosis as a result of the loss of the BMP co-receptor hemojuvelin.
To further explore whether BMP6 is a ligand for hemojuvelin, purified BMP6 alone, HJV.Fc alone or the combination of BMP6 and HJV.Fc were incubated in solution, and complexes containing HJV.Fc were pulled down with protein A beads. Protein blotting of eluates with anti-BMP6 showed that an 18-kDa protein corresponding to the predicted size of BMP6 monomer was pulled down in the presence of HJV.Fc (Fig. 4, arrow) . No 18-kDa band was seen on the blots of pulldowns from the solutions containing BMP6 alone or HJV.Fc alone (Fig. 4) . These data demonstrate a direct interaction between BMP6 and HJV.Fc.
Next, we examined the ability of exogenous BMP6 to regulate hepcidin expression and iron metabolism in vivo. Mice were injected intraperitoneally (i.p.) with a single dose of exogenous BMP6 at 250 or 1,000 mg per kg body weight. BMP6 administration significantly increased hepatic expression of Id1 mRNA, which we assessed as a Figure 3 Bmp6-null mice show reduced hepatic hepcidin expression, increased spleen ferroportin expression, increased serum iron and transferrin saturation, increased liver, heart, and pancreas iron content, and reduced spleen iron content. (a-g) Results of analyses of 8-week-old male Bmp6-null mice (n ¼ 5) and strain-matched wildtype control mice (WT, positive control (Supplementary Fig. 6 ). BMP6 administration also significantly increased hepatic Hamp mRNA expression (Fig. 5a ) and caused dose-dependent reductions in serum iron (Fig. 5b) and serum transferrin saturation (Fig. 5c) .
Together, these data suggest that BMP6 is a ligand for hemojuvelin and that BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism in vivo. Numerous other BMP ligands have been shown to regulate hepcidin when added exogenously in vitro or in vivo, including BMP2, BMP4, BMP5, BMP7 and BMP9 (refs. 3,4,13,17). We have also previously shown that endogenous BMP2, BMP4 and BMP6 all contribute to basal hepcidin expression in HepG2 cells 4 . Thus, it is not surprising that inhibition of BMP2 and BMP4 by DRAGON.Fc inhibits hepcidin expression in these cells. However, it is well established that cell-based assays do not accurately mirror the in vivo regulation of hepcidin by iron, as iron increases hepcidin expression in vivo but decreases hepcidin expression in vitro under most conditions 5, 10, 25 . One reason for this discrepancy may be that the complement of BMP ligands and receptors that regulate hepcidin expression in vitro is different from those that regulate hepcidin expression in response to iron in vivo. We hypothesize that HJV.Fc and anti-BMP6 inhibit hepcidin expression in vivo by binding to endogenously secreted BMP6 and preventing its interaction with cell-surface signaling receptors. We hypothesize that DRAGON.Fc does not affect hepcidin expression in vivo because (i) it is a less potent inhibitor of BMP6 than HJV.Fc and does not significantly inhibit BMP6 at the doses used in this study, and (ii) in contrast to the in vitro experiments, endogenous BMP2 and BMP4 ligands do not significantly contribute to hepcidin regulation in vivo. Indeed, the liver is presumably the source of the endogenous BMPs that regulate hepcidin, and a recent study reported that hepatic Bmp6 mRNA levels vary concordantly with Hamp mRNA levels in response to dietary iron content, whereas Bmp2 mRNA levels are only slightly upregulated under extreme iron overload and Bmp4 mRNA levels are not modulated by dietary iron 26 . We also did not find changes in hepatic Bmp2 and Bmp4 mRNA levels in Bmp6-null mice despite significant iron overload ( Supplementary Fig. 7) . Notably, Bmp2 and Bmp4 mRNA abundance were increased 2.5-to 6-fold in the bone of Bmp6-null mice (P. Simic, I. Orlic, V. Kufner and S.V., unpublished data), suggesting that BMP2 and BMP4 are differentially regulated in different tissues and may compensate for the loss of BMP6 function in some tissues but do not compensate for the lack of BMP6 to regulate hepcidin expression and iron metabolism.
The Bmp6-null mice contain a neomycin cassette, raising the possibility that expression of neighboring genes might also be affected, as described in other mouse models 27 . The closest neighboring gene to Bmp6 is that encoding thioredoxin domain-containing protein 5 (Txndc5), 547 bp away. Expression of Txndc5 mRNA was similar in Bmp6-null and wild-type mice as measured by RT-PCR ( Supplementary Fig. 7 ). Although we cannot rule out small changes in Txndc5 mRNA levels by this technique, our interventional data showing that BMP6 administration increases hepcidin and reduces serum iron, while endogenous BMP6 inhibition reduces hepcidin expression and increases serum iron, lend further support to the hypothesis that it is the loss of BMP6 that is the main cause of the iron-overload phenotype in Bmp6-null mice. Our data suggest that selective BMP6 inhibitors may be effective agents for treating anemia of inflammation due to hepcidin excess. The lack of any other notable phenotype in Bmp6-null mice suggests that a more selective inhibitor may be better tolerated, with fewer offtarget effects. Additionally, BMP6-like agonists may provide an alternative treatment strategy for managing iron-overload disorders in patients resistant to current therapies. Although no human patients with BMP6 mutations have yet been described, our data also suggests that BMP6 mutations or BMP6 gene variants may function as another cause of hereditary hemochromatosis or a modifier of disease penetrance.
METHODS
cDNA. cDNA encoding codon-optimized DRAGON.Fc was generated by GenScript Corp., based on the extracellular domain of human DRAGON protein sequence upstream of the predicted glycosylphosphatidylinositol anchor (UniProtKB/Swiss-Prot accession code Q6NW40, amino acids 1-409) and the human IgG1 Fc sequence (from the Signal pIg plus vector (R&D Systems) and GenBank AF150959).
Production and purification of DRAGON.Fc and HJV.Fc. cDNA encoding DRAGON.Fc was transfected using 239fectin (Invitrogen) into Freestyle 293-F cells (Invitrogen) according to the manufacturer's instructions. Transfected cells were cultured in GIBCO Freestyle 293 Expression medium (Invitrogen) shaking at 110 r.p.m. in a humidified 8% CO 2 incubator at 37 1C. Seven days after transfection, cells were pelleted by centrifugation, and DRAGON.Fc was purified from the medium via one-step protein A affinity chromatography using Hi-Trap rProtein A FF columns (Amersham Biosciences) as previously described 21 . HJV.Fc was produced as previously described 4 . To determine purity and to quantify protein concentration, DRAGON.Fc and HJV.Fc were subjected to reducing SDS-PAGE followed by Bio-safe Coomassie blue staining (Bio-Rad) as well as protein blotting with anti-hemojuvelin 3 , anti-DRAGON 20 and goat anti-human Fc (Jackson ImmunoResearch Laboratories) as previously described 3, 20 . Protein concentration was also quantified by the bovine serum albumin protein assay (Pierce).
Production of BMP6. Purified recombinant human BMP6 was prepared as previously described 28 . Lyophilized BMP6 was dissolved in 20 mM sodium acetate, 5% mannitol solution, pH 4.0, for animal injections.
Luciferase assay. Hepcidin promoter-luciferase reporter assays in hepatomaderived Hep3B cells were carried out using the Dual-Luciferase Reporter Assay System (Promega) as previously described 3, 4 with the following modifications. Hep3B cells transfected with the hepcidin promoter-luciferase reporter 3 and control Renilla luciferase vector (pRL-TK) were serum starved in a-MEM with L-glutamine (Invitrogen) supplemented with 1% FBS for 6 h, followed by stimulation with 25 ng ml -1 BMP2 (kindly provided by V. Rosen, Harvard School of Dental Medicine), BMP4, BMP6, or BMP7, 50 ng ml -1 BMP5 or kg or an equal volume of isotonic saline three times per week for 3 weeks. Twenty-four hours after the last injection, mice were killed and blood and livers were harvested for measurement of iron parameters and hepcidin expression. Results for both DRAGON.Fc and HJV.Fc doses were similar and were therefore combined into one group.
For anti-BMP6 injection experiments, 8-week-old 129S6/SvEvTac mice received an i.p. injection of monoclonal anti-human BMP6 (R&D Systems) at 10 mg per kg daily for 3 d or at 5 mg per kg three times weekly for 3 weeks. Control mice received an i.p. injection of an equal volume of isotonic saline using the same dosing regimen. Based on the assumption that anti-BMP6 would function by a mechanism similar to that of HJV.Fc protein, by binding and sequestering endogenously produced BMP6 ligand, we chose the expected minimal effective dose of anti-BMP6 for these in vivo experiments based on our in vitro data obtained using this antibody and our experience with HJV.Fc protein. Twelve hours after the last injection, mice were killed and blood and livers were harvested for measurement of iron parameters and hepcidin expression.
For BMP6 injection experiments, 8-week-old 129/SvEvTac mice received an i.p. injection of BMP6 at 250 or 1,000 mg per kg or an equal volume of vehicle alone (20 mM sodium acetate, 5% mannitol solution, pH 4.0). Six hours after injection, mice were killed and blood, livers and spleens were harvested for measurement of iron parameters and hepcidin expression. A time point of 6 h was chosen to capture both an increase in hepcidin expression and a resulting decrease in serum iron based on prior in vitro 3 and in vivo 4 data about the effects of BMP2 on hepcidin expression and serum iron, as well as preliminary dose-curve and time-curve data on the effects of BMP6 on hepcidin expression and serum iron in vivo (data not shown).
For Bmp6-null mouse experiments, 4-week-old and 8-week-old Bmp6-null mice and wild-type control mice of a similar age were killed and blood, livers, hearts, pancreases and spleens were harvested for measurements of iron parameters and hepcidin expression.
Quantitative real-time RT-PCR and RT-PCR. Total RNA was isolated from mouse livers using the RNeasy kit (Qiagen) according to the manufacturer's instructions. Real-time quantification of Hamp1 mRNA transcripts relative to Rpl19 was performed using two-step quantitative real-time RT-PCR as previously described 3, 4, 29 . Real-time quantification of Id1 mRNA was performed using primers summarized in Supplementary Table 1. Real time quantification of Bmp2, Bmp4 and Bmp6 mRNA from livers of Bmp6-null versus wild-type mice was performed using previously described primers 26 . Txndc5 mRNA was amplified from the livers of Bmp6-null and wild-type mice using primers summarized in Supplementary Table 1. Protein blotting. For ferroportin assays, spleen membrane preparations were prepared as previously described 4 . Protein concentrations were determined by BCA assay (Pierce). After solubilization in 1Â Laemmli buffer for 30 min at room temperature, 20 mg of protein per sample were resolved by reducing SDS-PAGE using pre-cast NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen) and transferred onto PDVF membranes (liquid transfer method). The blots were saturated with 10% nonfat dry milk in TBS-T) (50 mM Tris-HCl, 150 mM NaCl, 0.1% and probed overnight at 4 1C with 2.5 mg ml -1 antiferroportin (diluted in TBS-T with 5% nonfat milk) 30 . Following a wash with TBS-T, the blots were incubated with 1:5,000-diluted peroxidase-coupled goat anti-rabbit IgG (Sigma) for 1 h. Detection was performed with the enhanced chemiluminescence ECL method (Perkin Elmer). Blots were stripped and reprobed for b-actin expression as a loading control as previously described 3 . Chemiluminescence was quantified using IPLab Spectrum software version 3.9.5 r2 (Scanalytics).
Serum and tissue iron measurements. Serum was collected and analyzed for iron concentration and unsaturated iron-binding capacity as previously described 4 . Total iron-binding capacity and transferrin saturation were calculated as previously described 4 . Quantitative measurement of nonheme iron was performed on liver, spleen, heart and pancreas as previously described 4 .
Histology. Tissues from Bmp6-null and wild-type mice were fixed in 2% paraformaldehyde followed by 2% ethanol and embedded in paraffin. Sections were cut at 5 mm, deparaffinized in xylene and hydrated to distilled water. Sections were then placed in staining solution, consisting of equal volumes of 2% potassium ferrocyanide (Electron Microscopy Sciences) and 2% hydrochloric acid, for 60 min at room temperature. The sections were rinsed in distilled water, counterstained in 0.2% safranin O (Electron Microscopy Sciences) for 2 min and washed in 1% acetic acid, before being dehydrated in 95% alcohol and then absolute alcohol, cleared in xylene and mounted in DPX medium.
Pulldown assay. BMP6 (1 mg, R & D Systems) alone, HJV.Fc (5 mg) alone, or BMP6 (1 mg) in combination with HJV.Fc (5 mg) were incubated at 4 1C overnight in 500 ml of 50 mM Tris-HCl, 150 mM NaCl, 0.2% Tween-20, pH 7.4. The solutions were then incubated for 3 h at 4 1C with protein A beads (Pierce Biotechnology) that had been blocked with 1% BSA. The beads were washed and proteins were eluted with reducing 1Â Laemmli sample buffer. Eluted protein was separated by SDS-PAGE and subjected to protein blot analysis under reducing conditions using a rabbit polyclonal anti-BMP6 (1:500) 28 . Protein blot analysis of the above solutions before protein A pulldown was also performed under reducing conditions using rabbit polyclonal anti-BMP6 (1:500) as above and goat anti-human Fc (Jackson ImmunoResearch Laboratories) as previously described 3 .
Statistics. A two-tailed Student's t-test with P o 0.05 was used to determine statistical significance.
